King, Natalie E.
Courtney, Jo-Maree
Brown, Lachlan S.
Fortune, Alastair J.
Blackburn, Nicholas B.
Fletcher, Jessica L.
Cashion, Jake M.
Talbot, Jana
Pébay, Alice
Hewitt, Alex W.
Morris, Gary P.
Young, Kaylene M.
Cook, Anthony L.
Sutherland, Brad A. http://orcid.org/0000-0002-0791-0950
Funding for this research was provided by:
National Health and Medical Research Council (APP1137776, APP1163384)
Medical Research Future Fund (EPCD000008)
Multiple Sclerosis Australia (19-0696, 20-137, 21-3-023, 22-4-097)
University of Tasmania College of Health and Medicine
Menzies Institute for Medical Research
Irene Phelps Charitable Trust
Article History
Received: 18 October 2023
Accepted: 16 February 2024
First Online: 3 March 2024
Declarations
:
: The TOB-00220 iPSC line was cultured under the project “Use of induced pluripotent stem cell lines from repositories, commercial sources, and academic collaborators” approved by the University of Tasmania Human Research Ethics Committee (Project Number H26563 approved on 23rd November 2021). MNZTASi019-A, MNZTASi021-A and MNZTASi022-A, were purchased from the MS Stem biobank (Menzies Institute for Medical Research, Hobart, Tasmania, Australia) and had been previously generated under the project “Investigating molecular mechanisms of Multiple Sclerosis in induced pluripotent stem cells” approved by the University of Tasmania Human Research Ethics Committee (Project Number H16915 approved on 12th December 2017).
: All participants provided consent for participation in the research and publication of the resulting data.
: The authors declare that they have no competing interests.